Effect of a Bone Morphogenetic Protein-2-derived peptide on the expression of tumor marker ZNF217 in osteoblasts and MCF-7 cells

Zinc Finger Protein 217 (ZNF217), a transcription factor and oncogene product, has been found to dysregulate Bone Morphogenetic (BMP) signaling induce invasion in breast tumors. In this study, the effect of BMP-2 or an active peptide, AISMLYLDEN, on expression ZNF217 , BMP4 CDK-inhibitor p21 gene, CDKN1A was investigated MCF-7 cancer cells. parallel, entire protein (BMP-2) as well aforementioned peptide were hDPSCs during osteogenic differentiation. The treatment cells with different concentrations AISMLYLDEN showed that addition 22.6 ng/ml more effective comparison other used concentrations. particular, 48 h after treatment, mRNA levels substantially increased contrast which decreased. These results are strongly supported by BrdU assay clearly indicated inhibition cell proliferation. Taken together, these open ways for concurrent use, at appropriate concentrations, conventional therapeutic tumors metastatic tendency bones. Regarding its differentiation into osteocytes, osteocalcin, marker, enhanced osteogenesis higher degree without however altering levels, remained expected non-cancer • reduce proliferation increase specific concentration, reduces expressions remain peptide-treated osteocytes.